Pemigatinib

Who we are

  • April 5, 2022
    Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
  • April 5, 2022
    The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy